REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 163 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $904,895 | +3.2% | 8,875 | -8.0% | 0.00% | 0.0% |
| Q1 2023 | $877,015 | +3202.6% | 9,646 | +1280.0% | 0.00% | – |
| Q4 2022 | $26,555 | +89.7% | 699 | +27.8% | 0.00% | – |
| Q3 2022 | $14,000 | -65.9% | 547 | -59.1% | 0.00% | – |
| Q2 2022 | $41,000 | -31.7% | 1,339 | -26.6% | 0.00% | – |
| Q1 2022 | $60,000 | +1100.0% | 1,824 | +930.5% | 0.00% | – |
| Q4 2021 | $5,000 | -44.4% | 177 | +88.3% | 0.00% | – |
| Q3 2021 | $9,000 | -89.9% | 94 | -85.0% | 0.00% | – |
| Q2 2021 | $89,000 | +9.9% | 627 | -22.4% | 0.00% | – |
| Q1 2021 | $81,000 | -36.2% | 808 | -21.4% | 0.00% | – |
| Q4 2020 | $127,000 | +78.9% | 1,028 | +41.2% | 0.00% | – |
| Q3 2020 | $71,000 | -32.4% | 728 | +7.2% | 0.00% | – |
| Q2 2020 | $105,000 | +4.0% | 679 | -3.7% | 0.00% | – |
| Q1 2020 | $101,000 | +102.0% | 705 | +187.8% | 0.00% | – |
| Q4 2019 | $50,000 | +4900.0% | 245 | +1533.3% | 0.00% | – |
| Q3 2019 | $1,000 | – | 15 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
| Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
| MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
| Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
| Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
| Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
| Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
| Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |